Medicine & Health

Updates every hour. Last Updated: 30-Mar-2026 01:15 ET (30-Mar-2026 05:15 GMT/UTC)

30-Mar-2026

New brain–heart guideline takes holistic approach to chronic disease management

Canadian Medical Association Journal
Peer-Reviewed Publication

A new brain–heart clinical practice guideline takes a holistic approach, integrating neurologic and mental health evidence with guidance for cardiovascular disease as many brain and heart conditions overlap and share similar risk factors. The guideline is published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.251137.

Journal

Canadian Medical Association Journal

Funder

Canada First Research Excellence Fund

30-Mar-2026

Preparing Canada’s health system for military conflicts

Canadian Medical Association Journal
Peer-Reviewed Publication

To prepare for major armed conflict involving Canada or its North Atlantic Treaty Organization (NATO) allies, the country must create a national framework for civilian–military medical integration, as the public health system would bear the burden of medical care, argue authors in a commentary in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.252067.

Journal

Canadian Medical Association Journal

29-Mar-2026

 

Exercise harder, not just longer, to reduce risk of disease and death

European Society of Cardiology
Peer-Reviewed Publication

People who get just a few minutes of vigorous activity daily are less likely to develop eight major diseases, including arthritis, heart disease and dementia, according to research published in the European Heart Journal.

Journal

European Heart Journal

29-Mar-2026

Extended low-dose apixaban and superficial vein thrombosis

JAMA Network
Peer-Reviewed Publication

About The Study: Extended low-intensity anticoagulation with apixaban was associated with a reduction in symptomatic superficial vein thrombosis (SuVT) in patients with provoked venous thromboembolism with enduring risk factors for recurrence. Further randomized clinical trials specifically focused on SuVT are needed to ascertain optimal antithrombotic strategies in broader populations at risk of SuVT.

Journal

JAMA Cardiology

29-Mar-2026

Serum neurofilament light chain and cardiovascular outcomes in patients with atrial fibrillation

JAMA Network
Peer-Reviewed Publication

About The Study: After multivariable adjustment, serum neurofilament light chain (sNfL) levels were associated with a broad range of adverse cardiovascular events and mortality in patients with atrial fibrillation (AF). Serum NfL may serve as a biomarker of cardiovascular risk in patients with AF.

Journal

JAMA Cardiology

28-Mar-2026

EMPEROR-preserved risk model and outcomes in the FINEARTS-HF trial

JAMA Network
Peer-Reviewed Publication

About The Study: The Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) risk models demonstrated good performance in Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF). Baseline risk did not modify the relative treatment effect of finerenone.

Journal

JAMA Cardiology

28-Mar-2026

Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease

JAMA Network
Peer-Reviewed Publication

About The Study: In this post hoc analysis, the dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide agonist tirzepatide, compared with the GLP-1 agonist dulaglutide, was associated with a lower incidence of a broad 6-component composite cardiovascular and kidney end point in patients with diabetes and established cardiovascular disease.

Journal

JAMA Cardiology